Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.95 USD
Change Today -0.01 / -0.51%
Volume 10.6K
ONTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

onconova therapeutics inc (ONTX) Snapshot

Open
$1.97
Previous Close
$1.96
Day High
$2.02
Day Low
$1.95
52 Week High
08/19/14 - $5.78
52 Week Low
08/4/15 - $1.95
Market Cap
42.3M
Average Volume 10 Days
22.8K
EPS TTM
$-2.65
Shares Outstanding
21.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCONOVA THERAPEUTICS INC (ONTX)

Related News

No related news articles were found.

onconova therapeutics inc (ONTX) Related Businessweek News

No Related Businessweek News Found

onconova therapeutics inc (ONTX) Details

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.

38 Employees
Last Reported Date: 05/15/15
Founded in 1998

onconova therapeutics inc (ONTX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $713.4K
Chief Financial Officer and Secretary
Total Annual Compensation: $347.9K
President of Research and Development
Total Annual Compensation: $450.7K
Senior Vice President of Product Development
Total Annual Compensation: $465.5K
Compensation as of Fiscal Year 2014.

onconova therapeutics inc (ONTX) Key Developments

Onconova Therapeutics, Inc. Appoints James J. Marino, Esq. to Board of Directors

Onconova Therapeutics, Inc. announced the appointment of James J. Marino J.D., MBA, to its Board of Directors. James J. Marino was a Partner at Dechert LLP for 28 years where he served as Managing Partner of the Princeton Office. Mr. Marino served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he served on the Board of Directors of Pharmacopeia Drug Discovery, Inc. from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital.

Onconova Therapeutics, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 10:15 AM

Onconova Therapeutics, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 10:15 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Ramesh Kumar, Co-Founder, Chief Executive Officer, President and Director.

Onconova Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Onconova Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's revenue was $114,000 compared to $447,000 a year ago. Loss from operations was $12,349,000 compared to $18,733,000 a year ago. Net loss was $12,367,000 compared to $18,716,000 a year ago. Net loss attributable to the company was $12,343,000 compared to $18,679,000 a year ago. Net loss per share of common stock, basic and diluted was $0.57 compared to $0.87 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTX:US $1.95 USD -0.01

ONTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTX.
View Industry Companies
 

Industry Analysis

ONTX

Industry Average

Valuation ONTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.6x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCONOVA THERAPEUTICS INC, please visit www.onconova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.